The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

The Name of the Year for 2024, according to the American Name Society, is “Ozempic," as in “Ozempic face,” “oat-zempic” and ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%. Novo Nordisk said a Phase 1b/2a clinical trial of amycretin ...

Both Novo Nordisk’s Ozempic (semaglutide ... Insurance coverage and manufacturer coupons can make GLP-1 RAs much more affordable with significant discounts to the list price.

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2 ...

The amount Medicare spent on Ozempic, Wegovy, and Rybelsus between November 2023 and October 2024 represents roughly 36% of Wall Street's consensus estimate for Novo Nordisk's total revenue in 2024.